TY - JOUR
T1 - Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA
T2 - Cohort profile
AU - Olson, Janet E.
AU - Ryu, Euijung
AU - Hathcock, Matthew A.
AU - Gupta, Ruchi
AU - Bublitz, Joshua T.
AU - Takahashi, Paul Y.
AU - Bielinski, Suzette J.
AU - St Sauver, Jennifer L.
AU - Meagher, Karen
AU - Sharp, Richard R.
AU - Thibodeau, Stephen N.
AU - Cicek, Mine
AU - Cerhan, James R.
N1 - Funding Information:
Funding The creation and operation of the Mayo Clinic Biobank is supported by funding provided by the Mayo Clinic Center for Individualized Medicine.
Funding Information:
1Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA 2Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA 3Division of Primary Care Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA 4Biomedical Ethics Research Program, Mayo Clinic, Rochester, Minnesota, USA 5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA Acknowledgements The authors wish to acknowledge the institutional leadership at Mayo Clinic for their foresight and support of this project, including Gianrico Farrugia, M.D. and Keith Stewart, M.B., Ch.B. We also thank the many efforts of the study coordinators who did the bulk of the work to successfully recruit all the participants. We especially thank Jody Morrisette for her leadership of the coordinator team.
Publisher Copyright:
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Purpose The Mayo Clinic Biobank was established to provide a large group of patients from which comparison groups (ie, controls) could be selected for case-control studies, to create a prospective cohort with sufficient power for common outcomes and to support electronic health record (EHR) studies. Participants A total of 56 862 participants enrolled (21% response rate) into the Mayo Clinic Biobank from Rochester, Minnesota (77%, n=43 836), Jacksonville, Florida (18%, n=10 368) and La Crosse, Wisconsin (5%, n=2658). Participants were all Mayo Clinic patients, 18 years of age or older and US residents. Findings to date Overall, 43% of participants were 65 years of age or older and female participants were more frequent (59%) than males at all sites. Most participants resided in the Upper Midwest regions of the USA (Minnesota, Iowa, Illinois or Wisconsin), Florida or Georgia. Self-reported race among Biobank participants was 90% white. Here we provide examples of the types of studies that have successfully utilised the resource, including (1) investigations of the population itself, (2) provision of controls for case-control studies, (3) genotype-driven research, (4) EHR-based research and (5) prospective recruitment to other studies. Over 270 projects have been approved to date to access Biobank data and/or samples; over 200 000 sample aliquots have been approved for distribution. Future plans The data and samples in the Mayo Clinic Biobank can be used for various types of epidemiological and clinical studies, especially in the setting of case-control studies for which the Biobank samples serve as control samples. We are planning cohort studies with additional follow-up and acquisition of genetic information on a large scale.
AB - Purpose The Mayo Clinic Biobank was established to provide a large group of patients from which comparison groups (ie, controls) could be selected for case-control studies, to create a prospective cohort with sufficient power for common outcomes and to support electronic health record (EHR) studies. Participants A total of 56 862 participants enrolled (21% response rate) into the Mayo Clinic Biobank from Rochester, Minnesota (77%, n=43 836), Jacksonville, Florida (18%, n=10 368) and La Crosse, Wisconsin (5%, n=2658). Participants were all Mayo Clinic patients, 18 years of age or older and US residents. Findings to date Overall, 43% of participants were 65 years of age or older and female participants were more frequent (59%) than males at all sites. Most participants resided in the Upper Midwest regions of the USA (Minnesota, Iowa, Illinois or Wisconsin), Florida or Georgia. Self-reported race among Biobank participants was 90% white. Here we provide examples of the types of studies that have successfully utilised the resource, including (1) investigations of the population itself, (2) provision of controls for case-control studies, (3) genotype-driven research, (4) EHR-based research and (5) prospective recruitment to other studies. Over 270 projects have been approved to date to access Biobank data and/or samples; over 200 000 sample aliquots have been approved for distribution. Future plans The data and samples in the Mayo Clinic Biobank can be used for various types of epidemiological and clinical studies, especially in the setting of case-control studies for which the Biobank samples serve as control samples. We are planning cohort studies with additional follow-up and acquisition of genetic information on a large scale.
KW - cohort
KW - electronic health records
KW - mayo clinic biobank
UR - http://www.scopus.com/inward/record.url?scp=85074716109&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074716109&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2019-032707
DO - 10.1136/bmjopen-2019-032707
M3 - Article
C2 - 31699749
AN - SCOPUS:85074716109
SN - 2044-6055
VL - 9
JO - BMJ open
JF - BMJ open
IS - 11
M1 - e032707
ER -